Product
Wegovy (semaglutide) tablets
Once-daily oral semaglutide tablet from Novo Nordisk, FDA-approved December 2025 for weight management and cardiovascular risk reduction in adults. Self-pay $149 to $299/month by…
$149/mo
Foundayo (orforglipron) tablets
Once-daily oral GLP-1 pill from Eli Lilly, FDA-approved April 1, 2026 for weight management in adults. Launch self-pay price from $149/month for the lowest dose; current per-dose prices under review.
At a glance
Self-pay from
Not verified
no official price confirmed yet
How it is taken
Oral tablet, once daily, no food or water restrictions (per Lilly)
FDA status
FDA-approved
Data last checked
September 20, 2026
Needs review
FDA-approved for
- Reduce excess body weight and maintain weight reduction in adults with obesity, or overweight with at least one weight-related condition
Boxed warning: Risk of thyroid C-cell tumors (as reported at approval). This page is not medical advice. Talk to a licensed clinician.
Self-pay price by dose
We have not verified a current price yet
Launch price announced April 1, 2026: from $149/month for the lowest dose. Current per-dose prices: Needs review
We only list a price once we can confirm it from an official source. Ask the pharmacy for a quote for your prescribed dose.
Other ways to pay
Commercial insurance savings
As little as $25/month with the savings card (per Lilly, April 2026)
Medicare Part D
$50/month for eligible beneficiaries from July 1, 2026 (per Lilly, April 2026)
How the price compares
Lowest standard self-pay price per month from each manufacturer’s own pharmacy. Introductory offers and insurance prices are excluded. Medications, doses and approved uses differ, so this is a price reference, not a treatment comparison.
Key facts
- Medication class
- Oral small-molecule GLP-1 receptor agonist
- Active ingredient
- Orforglipron
- Manufacturer
- Eli Lilly and Company
- Prescription required
- Yes
About this medication
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist from Eli Lilly, approved by the FDA on April 1, 2026. It is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or overweight with at least one weight-related condition. According to Lilly, it can be taken at any time of day without food or water restrictions.
At launch, Lilly announced self-pay pricing starting at $149 per month for the lowest dose. We have not yet re-verified current prices for every dose, so no current price is listed here until we can confirm it.